Compound class:
Synthetic organic
Comment: SENS-111 (Seliforant) is an orally available small molecule histamine type 4 receptor antagonist, displaying an inhibitory effect on vestibular neuron activity.
|
|
No information available. |
Summary of Clinical Use |
Seliforant is under investigation for the treatment of acute unilateral vestibulopathy (AUV), also called vestibular neuritis. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03110458 | Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy | Phase 2 Interventional | Sensorion |